Dermatológia pre prax 4/2024

New possibilities for the use of botulinum toxin in the treatment of chronic dermatoses

Botulinum toxin type A is a neurotoxin produced by the anaerobic bacterium Clostridium botulinum. Due to its musclerelaxant effect, it is used primarily in the treatment of diseases associated with increased muscle activity or autonomic dysfunction. In recent years, in addition to its use in the treatment of neurological disorders, it has become known to the general public mainly for its use in aesthetic dermatology. In 1989, onabotulinumtoxin A (BTX-A) was originally approved by the US Food and Drug Administration (FDA) for the treatment of strabismus and blepharospasm. Following the gradual introduction of aesthetic indications, the popularity of BTX-A increased several times between 1997 and 2016. In addition to rejuvenating procedures, mesobotox also has potential in the treatment of various dermatological diseases, such as rosacea, seborrhea or acne. However, its use is still not officially approved and further studies are needed.

Keywords: botulinumtoxin type A, Clostridium botulinum, aesthetic dermatology, dermatological diseases